sibutramine has been researched along with Dyslipidemia in 2 studies
sibutramine: serotonin and norepinephrine transporter inhibitor; Meridia is tradename for sibutramine hydrochloride
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Svacina, S | 1 |
| Owen, K | 1 |
| Hendl, J | 1 |
| Matoulek, M | 1 |
| Brychta, T | 1 |
| Yanovski, SZ | 1 |
2 other studies available for sibutramine and Dyslipidemia
| Article | Year |
|---|---|
Comparison of lipid lowering effect of sibutramine in patients treated or not treated with statins--3 month follow-up.
Topics: Appetite Depressants; Cyclobutanes; Dyslipidemias; Humans; Hydroxymethylglutaryl-CoA Reductase Inhib | 2007 |
Pharmacotherapy for obesity--promise and uncertainty.
Topics: Anti-Obesity Agents; Appetite Depressants; Cannabinoid Receptor Antagonists; Cyclobutanes; Dyslipide | 2005 |